BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 15231679)

  • 1. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype.
    Congy-Jolivet N; Bolzec A; Ternant D; Ohresser M; Watier H; Thibault G
    Cancer Res; 2008 Feb; 68(4):976-80. PubMed ID: 18281470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
    de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
    Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.
    Böttcher S; Ritgen M; Brüggemann M; Raff T; Lüschen S; Humpe A; Kneba M; Pott C
    J Immunol Methods; 2005 Nov; 306(1-2):128-36. PubMed ID: 16181633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
    Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
    Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
    J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
    Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
    Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
    Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
    J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing.
    Mota G; Moldovan I; Calugaru A; Hirt M; Kozma E; Galatiuc C; Brasoveanu L; Boltz-Nitulescu G
    Scand J Immunol; 2004 Mar; 59(3):278-84. PubMed ID: 15030579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
    Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
    Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
    Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
    Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
    Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
    Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.
    Lenart M; Trzyna E; Rutkowska M; Bukowska-Strakova K; Szaflarska A; Pituch-Noworolska A; Szczepanik A; Zembala M; Siedlar M
    Int J Mol Med; 2010 Sep; 26(3):435-42. PubMed ID: 20664961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
    Armour KL; Smith CS; Clark MR
    J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.